D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to conduct a double-blind, placebo-controlled study of
D-cycloserine (DCS) augmentation of behavior therapy in individuals with Body Dysmorphic
Disorder (BDD). Specifically, we intend to randomize 50 individuals with BDD to receive
either DCS (n = 25) or placebo (n = 25) one hour prior to 8 of 10 behavior therapy sessions.